FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607665721> ?p ?o ?g. }

• W2607665721 endingPage "1017" @default.
• W2607665721 startingPage "1006" @default.
• W2607665721 abstract "Abstract Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity associating with homologous recombination DNA repair defects. We now report targeted and whole-exome sequencing of serial circulating cell-free DNA (cfDNA) samples collected during this trial. Decreases in cfDNA concentration independently associated with outcome in multivariable analyses (HR for overall survival at week 8: 0.19; 95% CI, 0.06–0.56; P = 0.003). All tumor tissue somatic DNA repair mutations were detectable in cfDNA; allele frequency of somatic mutations decreased selectively in responding patients (χ2 P &lt; 0.001). At disease progression, following response to olaparib, multiple subclonal aberrations reverting germline and somatic DNA repair mutations (BRCA2, PALB2) back in frame emerged as mechanisms of resistance. These data support the role of liquid biopsies as a predictive, prognostic, response, and resistance biomarker in metastatic prostate cancer. Significance: We report prospectively planned, serial, cfDNA analyses from patients with metastatic prostate cancer treated on an investigator-initiated phase II trial of olaparib. These analyses provide predictive, prognostic, response, and resistance data with “second hit” mutations first detectable at disease progression, suggesting clonal evolution from treatment-selective pressure and platinum resistance. Cancer Discov; 7(9); 1006–17. ©2017 AACR. See related commentary by Domchek, p. 937. See related article by Kondrashova et al., p. 984. See related article by Quigley et al., p. 999. This article is highlighted in the In This Issue feature, p. 920" @default.
• W2607665721 created "2017-05-05" @default.
• W2607665721 creator A5000824765 @default.
• W2607665721 creator A5002972986 @default.
• W2607665721 creator A5003311852 @default.
• W2607665721 creator A5004770247 @default.
• W2607665721 creator A5005619823 @default.
• W2607665721 creator A5012423170 @default.
• W2607665721 creator A5013656851 @default.
• W2607665721 creator A5014432818 @default.
• W2607665721 creator A5018210007 @default.
• W2607665721 creator A5031522630 @default.
• W2607665721 creator A5032324017 @default.
• W2607665721 creator A5032426555 @default.
• W2607665721 creator A5040450413 @default.
• W2607665721 creator A5041969793 @default.
• W2607665721 creator A5042313475 @default.
• W2607665721 creator A5042372750 @default.
• W2607665721 creator A5056339622 @default.
• W2607665721 creator A5059792318 @default.
• W2607665721 creator A5062124476 @default.
• W2607665721 creator A5062820099 @default.
• W2607665721 creator A5064026461 @default.
• W2607665721 creator A5066136399 @default.
• W2607665721 creator A5066732452 @default.
• W2607665721 creator A5068436175 @default.
• W2607665721 creator A5069346188 @default.
• W2607665721 creator A5072378199 @default.
• W2607665721 creator A5073714829 @default.
• W2607665721 creator A5074540413 @default.
• W2607665721 creator A5077292948 @default.
• W2607665721 creator A5078001213 @default.
• W2607665721 creator A5080919044 @default.
• W2607665721 creator A5082993213 @default.
• W2607665721 creator A5085732690 @default.
• W2607665721 creator A5088696108 @default.
• W2607665721 date "2017-08-31" @default.
• W2607665721 modified "2023-10-17" @default.
• W2607665721 title "Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition" @default.
• W2607665721 cites W1549619413 @default.
• W2607665721 cites W1578291413 @default.
• W2607665721 cites W1893269340 @default.
• W2607665721 cites W1898580708 @default.
• W2607665721 cites W1972769310 @default.
• W2607665721 cites W1987783969 @default.
• W2607665721 cites W2006352011 @default.
• W2607665721 cites W2019607817 @default.
• W2607665721 cites W2050146329 @default.
• W2607665721 cites W2051025382 @default.
• W2607665721 cites W2065849886 @default.
• W2607665721 cites W2102209369 @default.
• W2607665721 cites W2116284235 @default.
• W2607665721 cites W2121098984 @default.
• W2607665721 cites W2129128353 @default.
• W2607665721 cites W2130875528 @default.
• W2607665721 cites W2134536765 @default.
• W2607665721 cites W2135924719 @default.
• W2607665721 cites W2139799027 @default.
• W2607665721 cites W2156923287 @default.
• W2607665721 cites W2161112598 @default.
• W2607665721 cites W2167331614 @default.
• W2607665721 cites W2170818614 @default.
• W2607665721 cites W2171972386 @default.
• W2607665721 cites W2213675269 @default.
• W2607665721 cites W2235405584 @default.
• W2607665721 cites W2292362441 @default.
• W2607665721 cites W2317040753 @default.
• W2607665721 cites W2403998898 @default.
• W2607665721 cites W2462985846 @default.
• W2607665721 cites W2551638656 @default.
• W2607665721 cites W2559738633 @default.
• W2607665721 cites W2574073098 @default.
• W2607665721 cites W2579690199 @default.
• W2607665721 cites W2592941899 @default.
• W2607665721 doi "https://doi.org/10.1158/2159-8290.cd-17-0261" @default.
• W2607665721 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6143169" @default.
• W2607665721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28450425" @default.
• W2607665721 hasPublicationYear "2017" @default.
• W2607665721 type Work @default.
• W2607665721 sameAs 2607665721 @default.
• W2607665721 citedByCount "310" @default.
• W2607665721 countsByYear W26076657212017 @default.
• W2607665721 countsByYear W26076657212018 @default.
• W2607665721 countsByYear W26076657212019 @default.
• W2607665721 countsByYear W26076657212020 @default.
• W2607665721 countsByYear W26076657212021 @default.
• W2607665721 countsByYear W26076657212022 @default.
• W2607665721 countsByYear W26076657212023 @default.
• W2607665721 crossrefType "journal-article" @default.
• W2607665721 hasAuthorship W2607665721A5000824765 @default.
• W2607665721 hasAuthorship W2607665721A5002972986 @default.
• W2607665721 hasAuthorship W2607665721A5003311852 @default.
• W2607665721 hasAuthorship W2607665721A5004770247 @default.
• W2607665721 hasAuthorship W2607665721A5005619823 @default.
• W2607665721 hasAuthorship W2607665721A5012423170 @default.
• W2607665721 hasAuthorship W2607665721A5013656851 @default.
• W2607665721 hasAuthorship W2607665721A5014432818 @default.
• W2607665721 hasAuthorship W2607665721A5018210007 @default.

• next